Land: Kanada
Sprache: Englisch
Quelle: Health Canada
SALBUTAMOL (SALBUTAMOL SULFATE)
SANDOZ CANADA INCORPORATED
R03AC02
SALBUTAMOL
5MG
SOLUTION
SALBUTAMOL (SALBUTAMOL SULFATE) 5MG
INHALATION
10ML(5MG/ML)
Prescription
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0108887006; AHFS:
CANCELLED POST MARKET
2017-05-25
_ _ _Sandoz Salbutanol Page 1 of 30_ PRODUCT MONOGRAPH PR SANDOZ SALBUTAMOL (salbutamol sulfate inhalation solution) 0.5% 5 mg/mL BRONCHODILATOR Beta 2 -adrenergic stimulant SANDOZ CANADA INC. 145 Jules-Léger Boucherville, QC J4B 7K8 Date of Revision: May 17, 2017 Submission Control No: 205188 _ _ _Sandoz Salbutanol Page 2 of 30_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS ................................................................................. 3 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS .................................................................................................... 8 DOSAGE AND ADMINISTRATION ................................................................................ 9 OVERDOSAGE ................................................................................................................ 11 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 11 STORAGE AND STABILITY ......................................................................................... 13 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 13 PART II: SCIENTIFIC INFORMATION ............................................................................... 14 PHARMACEUTICAL INFORMATION ......................................................................... 14 CLINICAL TRIALS .......................................................................................................... 15 DETAILED PHARMACOLOGY ........... Lesen Sie das vollständige Dokument